ResearcherMayo ClinicNo recent work listed
John R. Bergquist
Matched on ORCID iD 0000-0002-4142-4905; OpenAlex author ID A5003607398. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 6
- Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4144↗
- Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftmen… Co-author DOI 10.1016/j.tranon.2018.09.008↗
- Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/jco.2016.71.2315↗
- Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5762-6↗
- Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and a… Co-author DOI 10.1016/j.jamcollsurg.2016.02.009↗
- Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chem… First author DOI 10.1016/j.surg.2016.06.010↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mark Joseph Truty · 6 shared papers, 2016–2021 · strength 0.49
- Paper Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. DOI 10.1002/cam4.4144↗
- Paper Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts … DOI 10.1016/j.tranon.2018.09.008↗
- Paper Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. DOI 10.1200/jco.2016.71.2315↗
- Christopher R. Shubert · 5 shared papers, 2016–2021 · strength 0.39
- Paper Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. DOI 10.1002/cam4.4144↗
- Paper Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer. DOI 10.1200/jco.2016.71.2315↗
- Paper Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemothe… DOI 10.1245/s10434-016-5762-6↗
- Michael L. Kendrick · 4 shared papers, 2016–2021 · strength 0.30
- Paper Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. DOI 10.1002/cam4.4144↗
- Paper Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemothe… DOI 10.1245/s10434-016-5762-6↗
- Paper Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associat… DOI 10.1016/j.jamcollsurg.2016.02.009↗
- Michael B. Farnell · 3 shared papers, 2016–2017 · strength 0.18
- Paper Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemothe… DOI 10.1245/s10434-016-5762-6↗
- Paper Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associat… DOI 10.1016/j.jamcollsurg.2016.02.009↗
- Paper Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy com… DOI 10.1016/j.surg.2016.06.010↗
- Sean Patrick Cleary · 1 shared paper, 2021 · strength 0.12
- Travis Edward Grotz · 1 shared paper, 2021 · strength 0.12
- Cornelius A. Thiels · 1 shared paper, 2021 · strength 0.12
- Santhi Swaroop Vege · 1 shared paper, 2021 · strength 0.12
- Matthew C. Hernandez · 1 shared paper, 2019 · strength 0.10
- Jennifer L. Leiting · 1 shared paper, 2019 · strength 0.10
- Rondell Patrell Graham · 1 shared paper, 2019 · strength 0.10
- Lin Yang · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.